Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ACAdicet Bio, Inc. logo

Adicet Bio, Inc. (ACET)

NASDAQ Global Market · Currency in USD
$3.99 ▼ -0.29 (-6.78%)
At close: Oct 23, 4:00 PM ET. Market closed.
$3.98 ▼ -0.01 (-0.25%)
After hours: Oct 23, 7:45 PM ET

Summary

Previous Close
$4.28
Open
$4.22
Day's Range
$3.96 – $4.24
52 Week Range
$3.96 – $14.56
Volume
162,437
Avg. Volume
163,489
Market Cap
$37.35M
Beta (5Y Monthly)
1.63
PE Ratio (TTM)
--
EPS (TTM)
-$9.21
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
$0.00 (0.01%)
Ex-Dividend Date
Sep 21, 2018
1y Target Est
$27.00

Profile: Adicet Bio, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
102
CEO
Chen Schor

Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$1.56
DateEst.Actual
Aug 5, 2026-$1.69-$1.99Miss
May 13, 2026-$2.93-$1.88Beat
Mar 12, 2026-$2.99-$2.94Beat
Nov 5, 2025-$4.16-$4.64Miss
Aug 7, 2025-$4.86-$5.44Miss
May 6, 2025-$5.31-$4.96Beat

Analyst view

Consensus price target
$27.00 ▲ +576.7%
Range $27.00 – $27.00
Rating: Buy
Buy 75% · Hold 25% · Sell 0%

Get free alerts on ACET and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.